We are live on
!
Find out more
DFO
Duquesne Family Office Portfolio holdings
AUM
$3.38B
1-Year Est. Return
61.92%
This Fund
S&P 500
This Quarter
Est. Return
+16.31%
1 Year Est. Return
+61.92%
3 Year Est. Return
+280.57%
5 Year Est. Return
+393.65%
10 Year Est. Return
+4,147.23%
AUM
$4.49B
AUM Growth
+$432M
(+11%)
Cap. Flow
-$36.6M
Cap. Flow
% of AUM
-0.82%
Top 10 Holdings %
Top 10 Hldgs %
52.3%
Holding
93
New
28
Increased
13
Reduced
16
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$293M |
| 2 |
Invesco S&P 500 Equal Weight ETF
RSP
|
+$223M |
| 3 |
iShares MSCI Brazil ETF
EWZ
|
+$112M |
| 4 |
Sea Limited
SE
|
+$99.2M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$80.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$264M |
| 2 |
Insmed
INSM
|
+$172M |
| 3 |
Natera
NTRA
|
+$147M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$107M |
| 5 |
TSMC
TSM
|
+$65.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28.89% |
| 2 | Consumer Discretionary | 15.38% |
| 3 | Technology | 10.8% |
| 4 | Industrials | 9.68% |
| 5 | Communication Services | 5.22% |
Similar funds
VFCM
OAM
EFM
BG
DIA
5NCM
MCM
QCG
Duquesne Family Office's Q4 2025 Portfolio in Review
As of Q4 2025, Duquesne Family Office held 93 positions worth $4.49B, up 11% from $4.06B the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Duquesne Family Office's Q4 2025 filing shows 28 new, 13 increased, 16 reduced and 31 closed positions. Its largest new stake was State Street Financial Select Sector SPDR ETF: 5,495,600 shares worth $301M. The largest sale was Teva Pharmaceuticals, an estimated $264M.
By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 35% a quarter earlier, followed by Consumer Discretionary and Technology.
- Duquesne Family Office's largest Q4 2025 buy was State Street Financial Select Sector SPDR ETF: 5,495,600 shares worth $301M.
- Duquesne Family Office added most to Sea Limited in Q4 2025, an estimated $99.2M increase.
- Duquesne Family Office's biggest Q4 2025 reduction was Teva Pharmaceuticals, cutting an estimated $264M.
- Duquesne Family Office fully exited Verona Pharma in Q4 2025, selling an estimated $107M.
- Duquesne Family Office's ten largest holdings make up 52% of its $4.49B portfolio in Q4 2025.
- Duquesne Family Office opened 28 new positions and closed 31 in Q4 2025.
- Duquesne Family Office's portfolio value rose 11% quarter-over-quarter to $4.49B.
Based on Duquesne Family Office's 13F filing for Q4 2025, filed 17 Feb 2026.